RE:People will start waking up soon enough Lattice Biologics’ Covid-19 stem cell therapy
Lattice Biologics is set to study its amniotic fluid concentrate, AmnioBoost, for the treatment of patients suffering from acute respiratory distress syndrome (ARDS) caused by Covid-19.
The company believes that AmnioBoost possesses the potential to treat ARDS.
AmnioBoost is thought to have immunomodulatory properties that can act against the inflammatory processes linked to several diseases.
It acts via down-regulation of the production of the pro-inflammatory cytokines, increasing anti-inflammatory cytokines production and facilitating recruitment of natural anti-inflammatory cells.
AmnioBoost consists of interleukin (IL)-1beta, IL-1ra, TNF-alpha, IL-6, IL-8, IL-16, CCL2, CXCL7, MIF and GRO a / b / g, among other anti-inflammatory cytokines.
The company’s new research is based on recent data from a clinical study in China, where allogeneic mesenchymal stem cells (MSCs) cured or significantly improved outcomes in seven patients with severe Covid-19 pneumonia.
https://www.pharmaceutical-technology.com/news/can-fite-lattice-biologics-covid-19-treatments/